

DAFTAR PUSTAKA

- Akhmad Rokiban, & Kiky Maykasari. (2024). Evaluasi Penggunaan Obat Antituberkulosis (Oat) Pada Pasien Tb Paru Di Puskesmas Punggur Kabupaten Lampung Tengah Periode Oktober 2022 - Oktober 2023. *Jurnal Farmasi IKIFA*, 3(1), 59–70.
- Akkahadsee, P., Sawangjit, R., Phumart, P., Chaikyakunapruk, N., & Sakloetsakun, D. (2023). Systematic review and network meta-analysis of efficacy and safety of interventions for preventing anti-tuberculosis drug induced liver injury. *Scientific Reports*, 13(1), 19880. <https://doi.org/10.1038/s41598-023-46565-3>
- Al Sas, O., Prambudi, H., Nur Ega Ziza, G., & Analis Kesehatan An Nasher, A. (2025). *GAMBARAN KADAR KREATININ PADA PENDERITA TUBERKULOSIS (TBC)*. <https://doi.org/10.31004/jn.v9i1.31194>
- Alffenaar, J. W. C., de Steenwinkel, J. E. M., Diacon, A. H., Simonsson, U. S. H., Srivastava, S., & Wicha, S. G. (2022). Pharmacokinetics and pharmacodynamics of anti-tuberculosis drugs: An evaluation of in vitro, in vivo methodologies and human studies. In *Frontiers in Pharmacology* (Vol. 13). Frontiers Media S.A. <https://doi.org/10.3389/fphar.2022.1063453>
- Amal, S., Hidayah, H., Cahyadi, A., Farmasi, F., Buana, U., Karawang, P., & Barat, J. (2020). *ANTITUBERKULOSIS PADA PASIEN TB PARU DI RUMAH SAKIT 'X' KARAWANG*. 6(1), 11–22.
- Ananda, H. A., Ananda, H. A., Kurniawati, D., Komalia, R., Sari, U., & Banjarmasin, M. (2023). *Studi farmakovigilans terapi tuberkulosis paru pasien rawat jalan di rsud ulin banjarmasin*. 16–25.
- Badrinath, M., Chen, R. J., & John, S. (2024). Isoniazid Toxicity. *Journal of the American Medical Association*, 168(12), 1685. <https://doi.org/10.1001/jama.1958.03000120091025>
- BPOM. (2020a). Modul Farmakovigilans Dasar. In *BADAN PENGAWASAN OBAT DAN MAKANAN JAPAN INTERNATIONAL COOPERATION AGENCY*.
- BPOM. (2020b). MODUL FARMAKOVIGILANS UNTUK TENAGA PROFESIONAL KESEHATAN PROYEK "Ensuring Drug and food safety. In *MODUL FARMAKOVIGILANS UNTUK TENAGA PROFESIONAL KESEHATAN PROYEK "Ensuring Drug and food safety*.
- BPOM. (2020c). *MODUL FARMAKOVIGILANS UNTUK TENAGA PROFESIONAL KESEHATAN "Proyek Ensuring Drug and Food Safety."*

- Brown, M. R., & Schult, R. F. (2024). Isoniazid. *Encyclopedia of Toxicology, Fourth Edition: Volume 1-9, 5*, V5-701-V5-706. <https://doi.org/10.1016/B978-0-12-824315-2.00121-4>
- Dirga, A., Fadlila, R. N., & Kesrianti, A. M. (2024). Deteksi Dini Obesitas Berdasarkan Pemeriksaan Indeks Massa Tubuh (IMT) Pada Siswa SMA Wahyu Kota Makassar. *Agustus*, 2, 2676–2683. <https://journal.institercom-edu.org/index.php/multiple>
- Fadhilla, G., Sitti, F. P. H., Rahma, A., Matematika, F., Ilmu, D., & Alam, P. (2025). STUDI EFEK SAMPING ANTITUBERKULOSIS PADA PASIEN RAWAT JALAN DI SALAH SATU RUMAH SAKIT DI GARUT. *Acta Pharmaceutica Indonesia* |, 50(hlm), 79–88.
- Farhanisa, Kartika Untari, E., & Nansy, E. (2016). *KEJADIAN EFEK SAMPING OBAT ANTI TUBERKULOSIS (OAT) KATEGORI 1 PADA PASIEN TB PARU DI UNIT PENGOBATAN PENYAKIT PARU-PARU (UP4)*.
- Fitri Amirah. (2025). Laboratory in Infectious and Degenerative Diseases Study Of Use Of Antituberculosis Drugs (OAT) In One Of The Hospitals In Jember District. *Journal of Medical*, 3(2).
- Fortuna, T. A., Rachmawati, H., Hasmono, D., & Karuniawati, H. (2022). Studi Penggunaan Obat Anti Tuberkulosis (OAT) Tahap Lanjutan pada Pasien Baru BTA Positif. *Pharmacon: Jurnal Farmasi Indonesia*, 19(1), 62–71.
- Global tuberculosis report 2024*. (2024).
- He, K., Zhang, J., Du, X., He, X., Zeng, Y., & Liu, M. (2026). Common Adverse Reactions and Management Strategies of First-Line Anti-Tuberculosis Drugs. In *Infection and Drug Resistance* (Vol. 19, pp. 1–12). Dove Medical Press Ltd. <https://doi.org/10.2147/IDR.S564580>
- Hikmah, N., Sari, M., & Muhammad, L. O. (2023). Evaluasi Penggunaan Obat Antituberkulosis Pada Pasien Rawat Jalan Di Puskesmas Cipayung Kota Depok Tahun 2022. *Jurnal Farmasi Kryonaut*, 2(2), 8–13.
- Kamila, A. S., Futihat, C. E., Arianti, A. R., Farmasi, P. S., Mitra, S., Jl, K., & Raya, R. S. (2025). Efek Samping Obat Antituberkulosis (OAT) Lini Pertama pada Penderita TB Paru di Puskesmas X Kota Bekasi Periode Januari – Maret 2025. *Sainstech Farma*, 18(2), 64–71.
- Kasni, Hanafi, L. O. A., & Fauziah, R. (2024). Rasionalitas Penggunaan Obat Anti Tuberkulosis Pada Pasien Tuberkulosis Paru Di Puskesmas Poasia Kota Kendari Tahun 2021. *Jurnal Pharmacia Mandala Waluya*, 3(1), 1–11. <https://doi.org/10.54883/jpmw.v3i1.88>

- Kemenkes. (2020). *Pedoman Nasional Pelayanan Kedokteran Tata Laksana Tuberkulosis* (Vol. 17). Permenkes RI.
- Kemenkes. (2025). *KEPUTUSAN MENTERI KESEHATAN REPUBLIK INDONESIA*.
- KEMENKES. (2025). *Petunjuk Teknis Penatalaksanaan Tuberkulosis Sensitif Obat di Indonesia*.
- Kemenkes RI. (2020a). PEDOMAN NASIONAL PELAYANAN KEDOKTERAN TATA LAKSANA TUBERKULOSIS. In *KEMENTERIAN KESEHATAN REPUBLIK INDONESIA*.
- Kemenkes RI. (2020b). PEDOMAN NASIONAL PELAYANAN KEDOKTERAN TATA LAKSANA TUBERKULOSIS. In *KEMENTERIAN KESEHATAN REPUBLIK INDONESIA*.
- Kemenkes RI. (2020c). pedoman nasional pelayanan kedokteran tata laksana tuberkulosis. In *Kementerian Kesehatan Republik Indonesia*.
- Kemenkes RI. (2025). *Petunjuk Teknis Penatalaksanaan Tuberkulosis Sensitif Obat di Indonesia* (1st ed.). Kemenkes RI.
- Kementerian Kesehatan. (2025). *Buku Panduan Tenaga Medis dan Tenaga Kesehatan Tuberkulosis*.
- Kementerian Kesehatan RI. (2024). Laporan Situasi Tuberkulosis Indonesia Tahun 2024. Jakarta: Kementerian Kesehatan RI.
- Kinanti, S., & Rahmawaty, A. (2024a). *RATIONAL USE OF CATEGORY I ANTI-TUBERCULOSIS DRUGS IN ADULT PULMONARY TUBERCULOSIS PATIENTS AT BALKESMAS PATI*. 208–215.
- Kinanti, S., & Rahmawaty, A. (2024b). *RATIONAL USE OF CATEGORY I ANTI-TUBERCULOSIS DRUGS IN ADULT PULMONARY TUBERCULOSIS PATIENTS AT BALKESMAS PATI*. 208–215.
- Kristiani, W., Kurniawati, D., Saputri, R., Sari, U., & Banjarmasin, M. (2024). MONITORING EFEK SAMPING OBAT TUBERKULOSIS DI PUSKESMAS KERTAK HANYAR KABUPATEN BANJAR. *Jurnal Ilmiah Farmasi Akademi Farmasi*, 7(1), 26–42.
- Lee, N., Patel, P., & Nguyen, H. (2024). Ethambutol. *Kucers the Use of Antibiotics: A Clinical Review of Antibacterial, Antifungal, Antiparasitic, and Antiviral Drugs, Seventh Edition*, 2346–2360. <https://doi.org/10.1201/9781315152110>
- Lewinsohn, D. M., Leonard, M. K., Lobue, P. A., Cohn, D. L., Daley, C. L., Desmond, E., Keane, J., Lewinsohn, D. A., Loeffler, A. M., Mazurek, G. H.,

- O'Brien, R. J., Pai, M., Richeldi, L., Salfinger, M., Shinnick, T. M., Sterling, T. R., Warshauer, D. M., & Woods, G. L. (2017). Official American Thoracic Society/Infectious Diseases Society of America/Centers for Disease Control and Prevention Clinical Practice Guidelines: Diagnosis of Tuberculosis in Adults and Children. *Clinical Infectious Diseases*, 64(2), e1–e33. <https://doi.org/10.1093/cid/ciw694>
- Lewis, J. H., Korkmaz, S. Y., Rizk, C. A., & Copeland, M. J. (2024). Diagnosis, prevention and risk-management of drug-induced liver injury due to medications used to treat mycobacterium tuberculosis. *Expert Opinion on Drug Safety*, 23(9), 1093–1107. <https://doi.org/10.1080/14740338.2024.2399074>
- Luies, L., & Preez, I. du. (2020a). The echo of pulmonary tuberculosis: Mechanisms of clinical symptoms and other disease-induced systemic complications. *Clinical Microbiology Reviews*, 33(4), 1–19. <https://doi.org/10.1128/CMR.00036-20>
- Luies, L., & Preez, I. du. (2020b). The echo of pulmonary tuberculosis: Mechanisms of clinical symptoms and other disease-induced systemic complications. In *Clinical Microbiology Reviews* (Vol. 33, Number 4, pp. 1–19). American Society for Microbiology. <https://doi.org/10.1128/CMR.00036-20>
- Ma, H. W., Lee, H. S., & Ahn, J. Y. (2022). Analysis of Factors Affecting the Rate of Latent Tuberculosis Infection and Management in Pediatrics. *Children*, 9(10), 1–11. <https://doi.org/10.3390/children9101567>
- Ma'aruf, S. Y., Sharma, A., Fox, S., Duarte, R., Lange, C., & Tiberi, S. (2026). Management of adverse events in TB care and active TB drug safety monitoring. *Breathe*, 22(1), 250203. <https://doi.org/10.1183/20734735.0203-2025>
- Madania, M., Sy Pakaya, M., Sutriati Tuloli, T., & Abdulkadir, W. (2023). Gambaran Efek Samping Obat Antituberkulosis Pada Pasien Tuberkulosis. *Journal Syifa Sciences and Clinical Research*, 4(1), 267–274.
- Masrifah, D., Andarini, Y. D., & Kusumaningtyas, N. M. (2018a). *Pasien Tuberkulosis Rawat Jalan Di Rsud Kabupaten Caruban Periode Januari-Maret 2018*. 4(1), 1–7.
- Masrifah, D., Andarini, Y. D., & Kusumaningtyas, N. M. (2018b). *Pasien Tuberkulosis Rawat Jalan Di Rsud Kabupaten Caruban Periode Januari-Maret 2018*. 4(1), 1–7.

- Mereškevičienė, R., & Danila, E. (2025). The Adverse Effects of Tuberculosis Treatment: A Comprehensive Literature Review. In *Medicina (Lithuania)* (Vol. 61, Number 5). Multidisciplinary Digital Publishing Institute (MDPI). <https://doi.org/10.3390/medicina61050911>
- Mohammadnabi, N., Shamseddin, J., Emadi, M., Bodaghi, A. B., Varseh, M., Shariati, A., Rezaei, M., Dastranj, M., & Farahani, A. (2024). Mycobacterium tuberculosis: The Mechanism of Pathogenicity, Immune Responses, and Diagnostic Challenges. *Journal of Clinical Laboratory Analysis*, 38(23), 1–16. <https://doi.org/10.1002/jcla.25122>
- National Center for Biotechnology Information. (2026a). *PubChem Compound Summary for CID 1046, Pyrazinamide*. PubChem.
- National Center for Biotechnology Information. (2026b). *PubChem Compound Summary for CID 135398735, Rifampicin*. PubChem.
- National Center for Biotechnology Information. (2026c). *PubChem Compound Summary for CID 14052, Ethambutol*. PubChem.
- National Center for Biotechnology Information. (2026d). *PubChem Compound Summary for CID 3767, Isoniazid*. PubChem. <https://pubchem.ncbi.nlm.nih.gov/compound/Isoniazid>
- Ningsih, E. N., Abdulkadir, W., & Manno, M. R. (2025). Gambaran karakteristik pasien tuberculosis paru di puskesmas kota selatan kota gorontalo. *Jurnal Ilmiah Kajian Multidisipliner*, 9(11), 199–207.
- Prakoso, R. A., Rusidah, Y., & Sholikhati, A. (2025). PENGARUH LAMA PENUNDAAN PEMBUATAN SERUM TERHADAP PEMERIKSAAN KADAR SGOT DAN SGPT DI RS ASSUYUTHIYYAH PATI. *Jurnal Ilmiah Kajian Multidisipliner*, 9(8).
- Pramesti, R. A. D. P., & Anggondowati, T. (2025). KARAKTERISTIK DAN HASIL PENGobatan PASIEN TUBERKULOSIS SELAMA DAN PASCA-PANDEMI. *PREPOTIF: Jurnal Kesehatan Masyarakat*, 9(2), 3286–3298.
- Putri, T. A., Primadhamanti, A., & Angin, M. P. (2025a). Evaluasi Efek Samping Obat Anti Tuberkulosis (Oat) Pasien Tuberkolusis Paru Dewasa Di Rumah Sakit Imanuel Bandar Lampung. *Jurnal Ilmiah Wahana Pendidikan*, 11, 275–285.
- Putri, T. A., Primadhamanti, A., & Angin, M. P. (2025b). Evaluasi Efek Samping Obat Anti Tuberkulosis (Oat) Pasien Tuberkolusis Paru Dewasa Di Rumah Sakit Imanuel Bandar Lampung. *Jurnal Ilmiah Wahana Pendidikan*, Mei, 2025(A), 275–285.

- PUTRI, V. R., MUSLIM, Z., & SUSILO, A. I. (2024). Analisis Kejadian Efek Samping Obat Anti Tuberkulosis Di Kota Bengkulu. *Journal of Nursing and Public Health*, 12(1), 187–192. <https://doi.org/10.37676/jnph.v12i1.6368>
- Rao, G. N., Cirvello, J. D., Collins, B. J., Giles, H., Charles Lindamood, I., Rogers, T. R., Hoberman, A., Grimes, L., Sexton, T., Brine, D. R., & Sparacino, C. (1997). *Introduction*. <https://www.ncbi.nlm.nih.gov/books/NBK557192/>
- Rasdianah, N., Madania, M., Sutriati Tuloli, T., Abdulkadir, W. S., Ahmad, H., & Angraini Suwandi, T. B. (2023a). Studi Efek Samping Obat Antituberkulosis (OAT) Pada Pasien TB Paru. *Journal Syifa Sciences and Clinical Research*, 4(3), 707–717. <https://doi.org/10.37311/jsscr.v4i3.16657>
- Rasdianah, N., Madania, M., Sutriati Tuloli, T., Abdulkadir, W. S., Ahmad, H., & Angraini Suwandi, T. B. (2023b). Studi Efek Samping Obat Antituberkulosis (OAT) Pada Pasien TB Paru. *Journal Syifa Sciences and Clinical Research*, 4(3). <https://doi.org/10.37311/jsscr.v4i3.16657>
- Rasdianah, N., Madania, M., Tuloli, T. S., Abdulkadi, W. S., Ahmad, H., & Suwandi, T. B. A. (2022). Studi Efek Samping Obat Antituberkulosis (OAT) Pada Pasien TB Paru. *Journal Syifa Sciences and Clinical Research (JSSCR)*, 4(3), 707–717.
- Rasyid, S. A., Armayani, Yuniati, & Lio, T. M. P. (2020). Analysis of serum glutamic pyruvic transaminase and serum glutamic oxaloacetic transaminase levels in tuberculosis patients who are undergoing oat treatment in Kendari City General Hospital, Kota Kendari, Indonesia. *Infectious Disease Reports*, 12. <https://doi.org/10.4081/idr.2020.8737>
- Ravichandran, M., Rajaram, M., & Munusamy, M. (2022). *Pharmacovigilance of Antitubercular Therapy in Tuberculosis*. 14(2), 1–7. <https://doi.org/10.7759/cureus.21915>
- Resmi, M., Dokter, P., Indonesia, P., Arifin, P. M., Faisal, N., Agus, Y., Susanto, D., Jawab, P., Redaksi, P., Fachrucha, F., Pemimpin, W., Winariani, R., Redaksi, A., Fitriani, F., Permatasari, A., Jamal, T., Farih, Z., Mia, R., Ginanjar, E., ... Putra Pratomo, I. (2025). RESPIROLOGI INDONESIA SUSUNAN REDAKSI. In *J Respir Indo* (Vol. 34, Number 1). <http://www.jurnalrespirologi.org>
- Ristiani, N., & Oktariani, E. (2025). Impact of Antituberculosis Medication Adherence on Quality of Life in Pulmonary TB Patients. *Journal of Shifa Sciences and Clinical Research (JSSCR)*, 7(2), 234–242.
- Sajuni, S., Ikawaty, R., & Purnamayanti, A. (2024). Edukasi Kesehatan Tentang Tuberkulosis Pada Kader Surabaya Hebat Puskesmas Putat Jaya Surabaya. *I-*

Com: *Indonesian Community Journal*, 4(3), 2103–2109.
<https://doi.org/10.33379/icom.v4i3.5224>

Salsabilah, F. A. N., & Anggitasari, W. (2026). Studi Penggunaan Obat Antituberkulosis (OAT) Di Salah Satu Rumah Sakit Di Kabupaten Jember. *Journal of Medical Laboratory in Infectious and Degenerative Diseases*, 3(2), 9–13.

Sekarwati, M. D. (2025). Perbedaan Kadar Enzim Sgot Dan Sgpt Pada Pasien Tuberkulosis Paru Yang Sedang Mengonsumsi Obat Anti Tuberkulosis (Oat) Dalam Fase Intensif Dan Fase Lanjutan. *Mutiara : Multidisciplinary Scientific Journal*, 2(4), 412–423.

Setianingsih, S. A. (2020). *STUDI FARMAKOVIGILANS PENGOBATAN MDR-TB PADA PASIEN RAWAT JALAN DI RSUD EMBUNG FATIMAH KOTA BATAM TAHUN 2020 Study Of MDR-TB Treatment Pharmacovigilans In Outpatients At Embung Fatimah Hospital Batam City In 2020*.

Sulistiyanto, F. X., & Prasetyaningrum, E. (2019). Gambaran kepatuhan penggunaan obat pada pasien Tuberkulosis terhadap keberhasilan terapi di puskesmas “X” kabupaten Kudus, Jawa Tengah. *VISI KES : Jurnal Kesehatan Masyarakat*, (2), 234–242.

Taylor, A., Anand, S., Rose, J. S. M., Shah, S., Shah, H., Sethi, R., Huynh, K., Malik, K., & Shah, N. (2023). Rifampin. *Encyclopedia of Toxicology, Fourth Edition: Volume 1-9*, 8, V8-305-V8-310. <https://doi.org/10.1016/B978-0-12-824315-2.00695-3>

Uswatun, A., Rochjana¹⁾, H., Safirah, ;, & Laeman²⁾, A. (2024). PROFIL PENGGUNAAN OBAT ANTI TUBERKULOSIS PARU DI INSTALASI FARMASI RAWAT JALAN BPJS RUMAH SAKIT “X” JAKARTA PUSAT PERIODE JANUARI-DESEMBER 2022. In *Indonesian Journal of Health Science* (Vol. 4, Number 4).

Vellia, R. P., Zamharira, M., & Avrilya, I. S. (2024). Analisis Kejadian Efek Samping Obat Anti Tuberkulosis Di Kota Bengkulu. *Journal of Nursing and Public Health*, 12(1), 187–192.

Verencia, A., Naftali, Al Farizi, G. R., & Ovikariani. (2019). Studi Pola Penggunaan Obat Anti Tuberkulosis Pada Pasien Tuberkulosis Paru. *Jurnal Surya Medika (Jsm)*, 8(1), 161–167.

Wabula, S., Widyantara, A. B., Astuti, T. D., Studi, P., Terapan, S., Laboratorium, T., & Yogyakarta, U. A. (2024). ANALISIS KADAR SGOT DAN SGPT PADA PASIEN TUBERKULOSIS DALAM PENGOBATAN OAT DI RSU

PKU MUHAMMADIYAH YOGYAKARTA. *JURNAL KESEHATAN TAMBUSAI*, 5(September), 9152–9158.

WHO. (2002). *WHO PHARMACOVIGILANCE INDICATORS: A PRACTICAL MANUAL FOR THE ASSESSMENT OF PHARMACOVIGILANCE SYSTEMS* (p. 48). World Health Organization : Uppsala Monitoring Centre, WHO Collaborating Centre for International Drug Monitoring.

WHO. (2012). *A PRACTICAL HANDBOOK ON THE PHARMACOVIGILANCE OF MEDICINES USED IN THE TREATMENT OF TUBERCULOSIS ENHANCING THE SAFETY OF THE TB PATIENT*.

WHO. (2024). *Global Tuberculosis (TB)*.

Wulansari, R., Anjar, F., Setyani, R., Fina, S., & Puspasari, A. (2025). KUALITAS HIDUP PASIEN TUBERKULOSIS PARU BERDASARKAN INDEKS MASSA TUBUH QUALITY OF LIFE OF PULMONARY TUBERCULOSIS PATIENTS BASED ON THE BODY MASS INDEX. *Jurnal Keperawatan Malang (JKM)*, 10(01), 91–100. <https://doi.org/10.36916/jkm>

